First human test of OPT101 peptide begins
NCT ID NCT04589403
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tested the safety of a new drug called OPT101 in 14 healthy volunteers. Participants received either OPT101 or a placebo, and researchers monitored for side effects, vital signs, and lab changes. The study was completed and focused only on safety and how the drug moves through the body, not on treating any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- OPT101 (a 15-mer peptide based on mouse CD154 domain)
- What could go wrong
- This is a very early Phase 1 trial with only 14 healthy volunteers, so it cannot show whether OPT101 works for any disease. The main goal is safety, not effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
IMMUNOe Research
Centennial, Colorado, 80112, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Does injection location matter for a new Weight-Loss drug? a trial investigates
- Which medical adhesive stays put longest without itching? a head-to-head test in healthy women.
- Avocado at breakfast: a secret weapon for blood sugar and fullness?
- New eye drop aims to tame ocular pain in early trial
- Could a formula closer to breast milk boost baby development?
- Could a daily probiotic help you feel fuller and eat less?